MENU
CRDF
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Cardiff Oncology (CRDF) Earnings Date & Reports

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

A.I. Advisor
published Earnings

CRDF is expected to report earnings to rise 5.27% to -23 cents per share on May 01

Cardiff Oncology CRDF Stock Earnings Reports
Q1'25
Est.
$-0.23
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.01
Q1'24
Beat
by $0.03
The last earnings report on February 27 showed earnings per share of -21 cents, beating the estimate of -25 cents. With 1.57M shares outstanding, the current market capitalization sits at 200.24M.
View a ticker or compare two or three
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com